10x Genomics, Inc. filings document regulatory disclosures for a Nasdaq-listed life science technology company with Class A common stock. Form 8-K reports furnish quarterly and annual operating results, selected preliminary results and business updates related to single cell and spatial biology platforms, including instruments, consumables, software and product launches.
The filing record also includes definitive proxy materials covering board matters, executive compensation, equity awards and shareholder voting items, as well as Form 8-K disclosure for executive officer transitions and related compensation arrangements. These documents describe TXG's public-company governance, registered security, financial reporting events and material corporate updates.
10x Genomics, Inc. (TXG) is the issuer whose Class A common stock is covered by a Schedule 13G/A from reporting persons ARK Investment Management LLC and Catherine D. Wood. Each reports beneficial ownership of 6,272,998 shares, or 5.22% of the class, as of September 30, 2026. ARK reports sole voting power over 6,028,612 shares and shared voting power over 63,202; Wood reports shared voting power over 6,091,814. ARK reports sole dispositive power over 6,272,998 shares, while Wood reports shared dispositive power over that amount.
10x Genomics, Inc. director Suliman Shehnaaz sold 5,723 shares of Class A Common Stock in five reported transactions on September 22, 2026. The reported weighted average sale prices were $78.1959, $79.5114, $80.8164, $81.6699 and $82.2768 per share. The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026.
10x Genomics, Inc. (TXG) Chief Executive Officer Serge Saxonov reported five direct sales totaling 25,000 Class A common shares on September 22, 2026. The reported weighted-average sale prices were $78.2284 for 1,000 shares, $79.6195 for 2,000, $80.9033 for 9,300, $81.8254 for 9,900, and $82.3650 for 2,800 shares. The sales were made under a Rule 10b5-1 trading plan adopted November 29, 2025.
10x Genomics, Inc. (TXG) received a Rule 144 notice covering a proposed sale of 5,723 shares of its Class A common stock for the account of affiliate Shehnaaz Suliman through J.P. Morgan Securities LLC on Nasdaq. The shares were acquired via RSU awards vesting between August 21, 2024 and May 21, 2025.
10x Genomics, Inc. (TXG) reported that its Chief Financial Officer, Adam Taich, sold a total of 46,388 shares of Class A Common Stock on September 9, 2026 in three open-market transactions at weighted average prices ranging from about $63.68 to $65.26, under a Rule 10b5-1 trading plan adopted on June 10, 2026.
10x Genomics, Inc. (TXG) disclosed that officer Adam Taich has filed a notice of proposed sale of company common stock under Rule 144. The filing lists up to 46,388 shares of common stock to be sold through Morgan Stanley Smith Barney LLC, with an aggregate market value of $2,995,470.31 and total issuer common shares outstanding of 120,212,296 as of September 9, 2026.
The shares to be sold come from restricted stock granted by the issuer, including 39,272 shares dated August 21, 2025 and 7,116 shares dated May 21, 2025. The filing also reports that during the past three months, on August 24, 2026, Taich sold 17,166 shares of common stock for proceeds of $1,081,853.63.
10x Genomics, Inc. (TXG) director John R. Stuelpnagel reported selling a total of 20,000 shares of Class A common stock on September 3, 2026 in open-market transactions. The shares were sold in three blocks at weighted average prices around $60.66, $62.11, and $62.61, each executed across multiple trade prices, and no Rule 10b5-1 trading plan is reported.
10x Genomics, Inc. (TXG) reports that T. Rowe Price Associates, Inc. has filed a Schedule 13G disclosing beneficial ownership of 14,044,020 shares of its Class A common stock, representing 11.7% of the class. T. Rowe Price reports sole voting power over 13,511,751 shares and sole dispositive power over 14,044,020 shares.
T. Rowe Price Associates states that this filing should not be construed as an admission that it is the beneficial owner of these securities and expressly denies such beneficial ownership.
10x Genomics, Inc. (TXG) reports that Chief Executive Officer and director Serge Saxonov made a bona fide gift of 100 shares of Class A Common Stock on September 1, 2026, at a reported price of $0.00 per share. Following the gift, he held 1,075,249 Class A shares directly, and also had indirect ownership interests as trustee of the Andromeda Trust, the Y/S Descendants' Trust, and the Y/S Pot Trust. No Rule 10b5-1 trading plan is reported for this transaction.
10x Genomics, Inc. (TXG) is the issuer for which director John R. Stuelpnagel has filed a Rule 144 notice covering the potential sale of 20,000 shares of Class A common stock. The shares are held in the John R. Stuelpnagel Trust and were originally granted as founders shares on August 21, 2017.
The notice lists an aggregate market value of approximately $1.24 million for the 20,000 shares, compared with 120,212,296 Class A shares outstanding. The filing also reports that the trust sold 20,000 shares of 10x Genomics, Inc. on August 11, 2026 for about $1.16 million.